The TLR9 agonist ODN1826 suppressed tumor burden in a B16-F10 melanoma mouse model, and the most efficient treatment was the locally injected combination of the CpG oligonucleotide TLR9 agonist ODN1826 combined with systemic CTLA-4 blockade [362]. Here, TLR9 is linked to melanoma.